<code id='D838230E4D'></code><style id='D838230E4D'></style>
    • <acronym id='D838230E4D'></acronym>
      <center id='D838230E4D'><center id='D838230E4D'><tfoot id='D838230E4D'></tfoot></center><abbr id='D838230E4D'><dir id='D838230E4D'><tfoot id='D838230E4D'></tfoot><noframes id='D838230E4D'>

    • <optgroup id='D838230E4D'><strike id='D838230E4D'><sup id='D838230E4D'></sup></strike><code id='D838230E4D'></code></optgroup>
        1. <b id='D838230E4D'><label id='D838230E4D'><select id='D838230E4D'><dt id='D838230E4D'><span id='D838230E4D'></span></dt></select></label></b><u id='D838230E4D'></u>
          <i id='D838230E4D'><strike id='D838230E4D'><tt id='D838230E4D'><pre id='D838230E4D'></pre></tt></strike></i>

          hotspot

          hotspot

          author:knowledge    Page View:967
          US Capitol - SOTU
          Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

          WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

          It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

          advertisement

          Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Sage considers ways to reduce costs following FDA rejection
          Sage considers ways to reduce costs following FDA rejection

          DrewAngerer/GettyImagesSageTherapeuticssaidMondaythatitmayneedtoreducecosts,includingthroughemployee

          read more
          Wildfire smoke exposes gaps in outdoor worker protections
          Wildfire smoke exposes gaps in outdoor worker protections

          ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

          read more

          As biotech industry slumps, bioscience job market is upside down

          ChristineKao/STATAfterearningherdoctorateincellbiologyattheUniversityofPennsylvaniainJune,SierraColl